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We report herein, facile metabolite identification workflow on the anti-depressant nefazodone,
which is derived from accurate mass measurements based on a single run/experimental
analysis. A hybrid LTQ/orbitrap mass spectrometer was used to obtain accurate mass full scan
MS and MS/MS in a data-dependent fashion to eliminate the reliance on a parent mass list.
Initial screening utilized a high mass tolerance (10 ppm) to filter the full scan MS data for
previously reported nefazodone metabolites. The tight mass tolerance reduces or eliminates
background chemical noise, dramatically increasing sensitivity for confirming or eliminating
the presence of metabolites as well as isobaric forms. The full scan accurate mass analysis of
suspected metabolites can be confirmed or refuted using three primary tools: (1) predictive
chemical formula and corresponding mass error analysis, (2) rings-plus-double bonds, and (3)
accurate mass product ion spectra of parent and suspected metabolites. Accurate mass
characterization of the parent ion structure provided the basis for assessing structural
assignment for metabolites. Metabolites were also characterized using parent product ion m/z
values to filter all tandem mass spectra for identification of precursor ions yielding similar
product ions. Identified metabolite parent masses were subjected to chemical formula
calculator based on accurate mass as well as bond saturation. Further analysis of potential
nefazodone metabolites was executed using accurate mass product ion spectra. Reported mass
measurement errors for all full scan MS and MS/MS spectra was 3 ppm, regardless of
relative ion abundance, which enabled the use of predictive software in determining product
ion structure. The ability to conduct biotransformation profiling via tandem mass spectrom-
etry coupled with accurate mass measurements, all in a single experimental run, is clearly one
of the most attractive features of this methodology. (J Am Soc Mass Spectrom 2006, 17,
363–375) © 2006 American Society for Mass SpectrometryMetabolite identification constitutes an impor-tant paradigm at various stages of drug dis-covery and development. In the early discov-
ery stage, it is crucial to identify metabolic soft spots in
lead chemical series to provide feedback to medicinal
chemists for further optimization of the lead com-
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doi:10.1016/j.jasms.2005.11.014pounds. Metabolite identification studies at this stage
are usually designed to avoid metabolic instability that
may lead to extensive first pass metabolism and poor
oral bioactivity [1]. In addition, early metabolite identi-
fication studies are also extensively utilized to minimize
potential safety concerns that may arise from bioactiva-
tion of lead compounds to electrophilic reactive inter-
mediates [2]. For a drug candidate in preclinical devel-
opment an early understanding of the in vivo metabolic
fate is essential since metabolites can contribute to
pharmacologic action or possess toxicological conse-
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tivity, sensitivity, and speed of analysis with minimal
sample processing, liquid chromatography tandem
mass spectrometry (LC-MS/MS) has become the
method of choice for metabolite identification in the fast
paced environment of drug discovery/development
[3]. Crude extracts from complex biological matrices
can be subject to metabolite identification studies di-
rectly on a LC-MS/MS. Complex metabolite profiles
can be chromatographically separated on an HPLC
column and full scan MS and product ion scan MS/MS
data generated on-line. The molecular weight of metab-
olites and localization of biotransformation sites can be
elucidated based on interpretation of MS/MS data
obtained by collision-induced dissociation (CID) of the
parent structure and the various metabolites.
Structural elucidation of metabolites is not always
straightforward, particularly in cases of complex re-
arrangement of chemical architecture leading to
unique metabolites whose structure(s) cannot be elu-
cidated by the usual LC-MS/MS methodology [3–5].
Likewise, the presence of metabolites with isobaric
molecular ions and/or competing fragment ions in
parent drug MS confound precise determination of
fragmentation pattern in the parent drug and its
metabolites [3, 6]. In the latter case, competing frag-
mentation pathways in parent and metabolite mass
spectra can afford product ions separated by as little
as 0.04 to 0.1 Da. Using low-resolution mass spec-
trometry, these minute differences in observed frag-
ment ion masses often preclude an unambiguous
elucidation of fragment ion structure and conse-
quently metabolite structure. In some instances, the
ensuing dogma may be resolved via synthesis of
stable isotope (e.g., 13C, 2H, 15N) derivatives of the
parent molecule [7]. However, such strategies may
hinder progress in a fast paced drug discovery envi-
ronment, since additional efforts/resources must be
dedicated towards the synthesis of stable isotope
analogs, which can often require multistep synthesis.
Supplementing low-resolution MS with accurate
mass measurements in metabolite identification stud-
ies can provide valuable information in distinguish-
ing isobaric molecular ions and provide unequivocal
proof of correct fragmentation patterns, resulting in a
significant increase in confidence towards predictions
of metabolite structure [8, 9]. While time-of-flight
(TOF) instrumentation is often used to acquire accu-
rate mass information [10, 11], the methodology
requires numerous LC runs to acquire accurate mass
on multiple product ions and can be potentially
viewed as time and cost prohibitive in a typical drug
discovery scenario. Difficulties associated with using
TOF technology are attributed to a dependence on
internal calibrants or lock masses for obtaining high
mass accuracy measurements or recalibration off-
line. In addition, mass accuracy may be compromised
at extremely low relative ion intensities resulting inmissed diagnostic ions that can be used to further
identify metabolites.
Recently, the combination of Orbitrap technology
with a linear ion trap has been shown to enable fast,
sensitive and reliable detection and identification of
small molecules regardless of relative ion abundance
[12, 13]. The orbitrap mass analyzer employs the trap-
ping of pulsed ion beams in an electrostatic quadro-
logarithmic field. This field is created between an axial
central electrode and a coaxial outer electrode. Stable
ion trajectories combine rotation around the central
electrode with harmonic oscillations along it. The fre-
quencies of axial oscillations and hence mass-to-charge
ratios of ions are obtained using fast Fourier transform
of the image current detected on the two split halves of
the outer electrode. The hybrid linear ion trap/orbitrap
mass spectrometer is related to the Finnigan LTQ FT in
combining fast scan speeds and high mass accuracy
measurements (within a few ppm) for precursor and
product ions on an LC timescale which is critical for
metabolic profiling. Furthermore, external calibration
can be used to obtain high mass accuracy (3 ppm) of
all measured spectra resulting in a simplified experi-
mental protocol.
As a demonstration of the capability of this de Novo
technology, we re-examined the metabolic pathways of
the non-tricyclic anti-depressant drug nefazodone in
NADPH-supplemented human liver microsomes utiliz-
ing accurate mass measurements of precursor and
MS/MS product ions for the parent drug and its me-
tabolites [14 –17]. Data-dependent MS/MS analyses
were conducted on a hybrid linear ion trap/orbitrap
mass spectrometer that enabled high-resolution/high
mass accuracy measurements on precursors and prod-
uct ions regardless of relative ion abundance and on a
LC-timescale [12, 13, 18]. Furthermore, increased mass
accuracy measurements helped in assigning fragment
ion structure for all anticipated and novel metabolites of
the drug.
Experimental
Materials
Nefazodone hydrochloride and NADPH were pur-
chased from Sigma-Aldrich (St. Louis, MO). Human
liver microsomes pooled from 53 individual donors
were purchased from BD Gentest (Woburn, MA).
Microsomal Incubations
Stock solutions of nefazodone were prepared in meth-
anol. The final concentration of methanol in the incu-
bation media was 0.2% (vol/vol). Incubations were
carried out at 37 °C for 60 min in a shaking water bath.
The incubation volume was 1 mL and consisted of the
following: 0.1 M potassium phosphate buffer (pH 7.4),
human liver microsomes (P450 concentration  0.5
M), NADPH (1.2 mM), and nefazodone (10 M). The
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before adding NADPH and incubations were termi-
nated by the addition of ice-cold acetonitrile (1 mL). The
solutions were centrifuged (3000 g for 15 min) [16], and
the supernatants were dried under a steady nitrogen
stream. The residue was reconstituted with mobile
phase and analyzed for metabolite formation.
LC-MS/MS Assay for Identification of Nefazodone
Metabolites
Metabolites were identified by a Finnigan LTQ orbitrap
mass spectrometer (Thermo Electron, Bremen, Ger-
many) and all ion acquisition was performed using the
orbitrap mass spectrometer. The LC system consisted of
a Hypersil Gold (1.9 M C18 50  2.1 mm) column, a
Finnigan Surveyor LC system comprising of an HPLC
with a built-in degasser, autosampler, and a Finnigan
LTQ orbitrap mass spectrometer. A constant flow rate
of 0.27 mL/min was used with a gradient from 3–95% B
in 35 min before column re-equilibration. Solvent A was
10 mM ammonium formate (0.1% formic acid) and
Solvent B was acetonitrile (100%). The scan event cycle
used a full scan mass spectrum at a resolving power of
15,000 (atm/z 400) and three corresponding data-depen-
dent MS/MS events acquired at a resolving power of
7500. The three most intense ions detected during full
scan MS triggered data dependent scanning. Data de-
pendent scanning was performed without the use of a
parent ion list. The microscan count for full and MS/MS
scan events were set to unity and a repeat count for
dynamic exclusion was set to three for verification.
MS/MS activation parameters used an isolation width
of 2 Da, normalized collision energy of 35%, and an
activation time of 30 milliseconds. Mass accuracy was
determined from an external calibration that was per-
formed the prior day.
Data Interpretation
All data were processed using Qual Browser (Thermo
Electron, San Jose, CA), which provides accurate
mass thresholds to filter data. In addition, chemical
formula calculator was used to provide chemical
formula and saturation values (ring-plus-double-
bonds [RDB]) for product ions of nefazodone and its
metabolites [19]. Fragmentation patterns were gener-
ated using Mass Frontier 4.0 (Thermo Electron) [20,
21]. Predictive fragmentation pattern was derived
from plausible protonation sites, subsequent isomer-
ization and even electron species, and bond satura-
tion (i.e., RDB). Comparisons between theoretical and
experimental product ion spectra further aided in the
identification of metabolite structures and site(s) of
biotransformation with the parent drug.Results and Discussion
Scheme 1 depicts the observed molecular ions [MH] ,
retention times [Rt, min], and calculated RDB values for
nefazodone and its metabolites. Figure 1 shows the total
ion chromatogram of a NADPH-supplemented human
liver microsomal incubation of nefazodone (10 M) that is
baseline subtracted from control experiments lacking
NADPH co-factor. In addition to unmetabolized nefaz-
odone, which eluted at 13.36 min, there are numerous
lower intensity peaks, which can be attributed to metab-
olites derived from the oxidation of nefazodone. Metabo-
lite profiling studies were initiated following a thorough
investigation of themass spectral fragmentation pattern of
the nefazodone parent molecule considering that determi-
nation of precise fragmentation pattern of the parent
molecule enhances confidence towards predicting bio-
transformation site(s) on the corresponding metabolite
product ion.
Figure 2 shows a product ion spectrum of nefaz-
odone resulting from one total scan comprised of a
single microscan. The total time for product ion spec-
trum acquisition was 340 milliseconds. The product ion
spectrum is dominated by the fragment ion m/z 274
(measured ion intensity 2.1  e07 counts and mass
error of 1.4 ppm) corresponding to the phenoxyethyl-
5-ethyltriazolone propyl motif. In addition, there are
several low intensity product ions that are consistent
with fragmentation spectra predicted from Mass Fron-
tier 4.0. The structures and corresponding mass errors
for these low intensity fragment ions are presented in
Figure 2. It is interesting to point out that despite large
differences in measured ion intensity between product
ions, the measured mass accuracy are quite comparable.
For example, there is ca. a 100-fold difference between
the measured ion intensities of the product ions at m/z
140 (5.7  e05) and at m/z 274 (2.1  e07), yet the
differences in the measured mass accuracy are fairly
comparable (2.8 and 1.4 ppm for the product ions at
m/z 140 and 274, respectively). In addition, the inset in
Figure 2 shows the lowest intensity product ions de-
tected from the single product ion spectrum. The prod-
uct ion at m/z 197 has a measured ion intensity of 8.2 
e03 and a measured mass error of 4.5 ppm. This repre-
sents almost a 3000-fold difference in measured ion
intensities without a significant compromise in product
ion assignment.
The structure of nefazodone presents a challenge for
interpretation of the product ion spectra due to isobaric
product ions that can be predicted to arise, based on site
of protonation and subsequent bond scission. For ex-
ample, the N-alkylsubstituted nitrogen atom in the
piperazine ring (Figure 2) provides a basic center for
charge retention that could potentially lead to multiple
bond scissions before observed product ion formation.
The competing product ions may have isobaric mass-
to-charge values separated by 0.05 Da (ca. 200 ppm),
and thus, one would need to rely on accurate mass
measurements for correct prediction of fragment ion
e an
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predicted by Mass Frontier 4.0 that would give rise to
the product ion at m/z 180. Assuming protonation is
occurring on the piperazine nitrogen shown in Figure 3,
the product ion of the “left” side of the nefazodone
structure would possess a mass of 180.0575 Da (Figure
3, Pathway A) while the product ion that arises from the
right hand side of the molecule will possess a mass of
180.1131 Da (Figure 3, Pathway B). The measured mass
of 180.1128 unambiguously proves that cleavage on the
right hand side of the nefazodone structure is the most
likely route to the m/z 180 product ion given that the
resulting mass error is only 2 ppm compared to 307
ppm for the product ion resulting from cleavage on the
left hand portion of nefazodone (Table 1). In addition to
the product ion at m/z 180, nefazodone fragmentation
affords other product ions that can be assigned multiple
structures that differ by less than 0.1 Da. Table 1 lists the
product ions observed following nefazodone collisional
activation. The experimentally observed mass-to-charge
values are listed with the predicted product ions from
Mass Frontier 4.0. Note that five out of the eight
product ions have predicted product ions with charge
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Figure 4 depicts a series of extracted ion chromato-
grams for various nefazodone metabolites. The ob-
served molecular ions and fragment ion spectra of these
metabolites are consistent with those previously re-
ported in the in vivo and in vitro metabolism studies on
nefazodone in humans [14 –17]. Individual metabolite
ions were initially extracted from the total ion chro-
matogram using m/z values for nefazodone metabolites
from previously published reports. A mass threshold of
10 ppm was used to determine “real” metabolite signal.
The benefits of using a high mass tolerance dramatically
improved signal-to-noise ratio and allowed an easy
determination of the presence of isomeric metabolites as
well as metabolites which were not predicted from
Mass Frontier 4.0 and/or theoretical reasoning. Further-
more, by reducing the background signal from each
extracted ion chromatographic trace, a difference in
signal intensity of ca. 2800 times is observed between
the greatest integrated peak area for the nefazodone
parent ion and the minor peak for the metabolite with
m/z at 484 (mass error  1.7 ppm) that eluted at 12.9
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carbonyl functionality within the molecule and this
metabolite appears to be an isomer of M9. In addition to
this set of isomeric metabolites of nefazodone, the
extracted ion chromatographic traces also indicated the
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Figure 1. Base peak chromatogram of a NADPH
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368 PETERMAN ET AL. J Am Soc Mass Spectrom 2006, 17, 363–375(Figure 5b), respectively. The mass accuracy associated
with each fragment ion resulted from comparison of
experimental values with predicted structures from
Mass Frontier 4.0. The spectrum shows the 20-fold
magnified region covering the mass range of 135 to 265
Da. The product ion spectra (Figure 5a) of the monohy-
droxynefazodone metabolite at a Rt of 11.42 min reveals
a single fragment ion at m/z 253 representing an addi-
tion of mass 16 to the fragment ion at m/z 237 in the
nefazodone parent ion spectra (see Figure 2) implicat-
ing the 3-chlorophenylpiperazine ring as the site of
hydroxylation. In contrast, the product ion spectrum
(Figure 5b) of the monohydroxylated nefazodone me-
tabolite at an Rt of 12.22 min depicts diagnostic frag-
ment ions at m/z 152, 170, 209, and 262. The mass error
for the product ion at m/z 209, which corresponds to the
3-chlorophenylpiperazine ring region within nefaz-
odone, is 0.3 ppm. The fragment ions at m/z 170 (mass
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additions of mass 16 to the fragment ions at m/z 154 and
m/z 246, respectively, in the product ion spectrum of
nefazodone implicates the ethyl group in the 5-ethyl-
triazolone motif as the site of monohydroxylation.
Overall, the structures of these metabolites M6 and M8
(see Scheme 1) are consistent with those reported in
previous studies [14 –17].
Accurate mass filtering of the full scan mass spectral
data also revealed the possibility of a second m/z 306
metabolite (M5 in Scheme 1), which eluted at 11.01 min
and appears to be an isomer of the previously charac-
terized metabolite M4 (see Scheme 1) that elutes at 10.83
min. Both metabolites are derived from downstream
metabolism of the N-dealkylated metabolite M3 that
has lost the 3-chlorophenylpiperazine ring. Data-depen-
dent MS/MS spectra for each of the m/z 306 metabolites
are presented in Figure 6. The resulting product ion
spectra for M4 (Figure 6a) contain the product ions at
m/z 140 (mass error  2.6 ppm) and 246 (mass error 
2.0 ppm), which are also present in the mass spectrum
of nefazodone. These ions along with the fragment ion
at m/z 288 (representative of the acylium ion derived
from carboxylic acid fragmentation) are in excellent
agreement with the previously reported mass spectrum
of M4 [14, 16]. The previously undisclosed m/z 306
metabolite eluting at 11.01 min shows additional diag-
nostic product ions that can be utilized to gain insight
into its structure (Figure 6b). Specifically the fragment
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Figure 5. Comparison of the MS/MS spectra o
 11.42 min) and M8 (Rt  12.25 min).ions at m/z 168 and 194 provide insight into the twodistinct sites of oxidative metabolism as shown in the
proposed structure for M5 in Scheme 1. The mass error
associated with each of the unique fragment ions is 1.1
and 1.9 ppm. The degree of bond saturation based on
the Mass Frontier derived chemical formula is calcu-
lated to be 4.5 and 5.5, which agrees with the predicted
product ion structure. We propose that M5 arises from
the P4503A4-mediated N-dealkylation of M9.
Further examination of the LC-MS/MS analysis of
nefazodone microsomal incubation was conducted to
probe for the formation of additional and perhaps
unanticipated metabolites. The fragment ions identified
in the mass spectrum of nefazodone were also utilized
in extracting metabolite ions from all data-dependent
MS/MS spectra, thus providing an alternate tool for
data analysis. Figure 7 shows extracted ion chromato-
grams for the product ions at m/z values of 140.0818
(Figure 7a) and 274.15,500 (Figure 7b) from MS/MS
spectra obtained from nefazodone microsomal incuba-
tions. The mass tolerance used for the extracted ion
chromatograms was 10 ppm and the precursor ion
yielding the selected product ions are listed at the top of
each peak. It is worth commenting on the selectivity
displayed in this analysis when using a tight mass
tolerance. For example, Figure 7a shows predominant
peaks at retention times 8.91, 10.67, 11.43, and 13.38
min. The baseline in between each of the major peaks is
magnified 20-fold. Inspection of the magnified region
reflects the degree of selectivity considering that addi-
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Figure 7. Extracted ion chromatograms for MS/MS product ions from the nefazodone parent drug.
Masses labeled indicate the precursor mass isolated for collisional activation. The mass threshold used
for chromatographic reconstruction is 10 ppm.
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and 10.24 min, respectively) are not found in Figure 7a.
The use of the linear trap/orbitrap hybrid arrangement
thus enables detection of all product ions within a wide
mass spectral window as opposed to SRM analysis
employed by triple quadrupole mass spectrometers.
Therefore, a more thorough interrogation in a post-
acquisition method can be done by probing the result-
ing data for evidence of additional metabolites via
different product ions from either the parent drug or
previously characterized metabolites of the parent
drug. In addition, the high mass accuracy data acquisi-
tion enables a selective and sensitive means of filtering
the resulting product ion spectra. Figure 7 underscores
the utility of this approach showing identification of
potential metabolites using only two nefazodone prod-
uct ions. Many more product ions could be used in an
exhaustive searching algorithm to thoroughly process
the data for identification of as many metabolites as
would be deemed necessary.
Further structural analysis of the metabolites identi-
fied via the accurate mass product ion filtering was also
examined using Qual Browser capability of this instru-
mentation. Using the elemental composition and ranges
of the nefazodone parent structure, each metabolite was
matched with a predicted chemical formula and RDB
value. Predicted isotopic distribution was also com-
pared to the experimentally determined ratios. An
example of the described strategy is shown in Figure 8.
Figure 8a shows an extracted ion chromatogram for the
m/z 502 ion filtered using a mass tolerance of 10 ppm
and reveals only one elution peak. The observed m/z
value of 502.22,138 was fitted with potential elemental
Figure 8. Extracted ion chromatogram for t
corresponding full scan MS. The screen captur
formula and theoretical mass-to-charge value ancompositions showed in the bottom left range from theQual Browser screen-capture. The 5 ppm mass toler-
ance was used for prediction of a singly charged species
and the RDB constraint was widened to accommodate
values ranging from 100 to 100. This range is for
demonstration purposes and can be reduced further to
better fit the parent and/or metabolite structure. As
shown in the screen capture image in Figure 8, the
formulas predict four possible elemental compositions
for the observed m/z value. The first two formulae are
associated with mass errors less than 1 ppm while the
latter two formulas have mass errors around 3 ppm.
Examination of the isotopic distribution indicates the
presence of one chlorine atom, which eliminates the
second and fourth formulae. The correct molecular
formula could also be determined based on other RDB
value information. In the current scenario, the resulting
ions formed from electrospray ionization are even-
electron species, and if they contain a charge, then their
bond saturation would result in a non-integer. As
shown in Figure 8, only the top choice shows a value
representing a protonated species, thus all other possi-
ble formulae could be eliminated. Finally, a comparison
of experimental and theoretical isotopic distributions
can also be used in structure elucidation. Figure 8
shows excellent agreement between the experimental
and theoretical distribution for the m/z 502 metabolite.
Figure 9 displays the low mass range for the data-
dependent product ion spectrum from the metabolite
with molecular ion at m/z 502, which is consistent with
dihydroxylation of the parent nefazodone molecule.
The base peak, which constitutes the ion at m/z 290
(mass error 2.1 ppm), is consistent with addition of 16
Da to the ion atm/z 274 identical to that observed for the
ihydroxynefazodone metabolite M10 and the
Qual Browser shows the predicted chemical
topic distribution.he d
e frommonohydroxy nefazodone metabolite M8 (m/z 486, Rt
ure o
372 PETERMAN ET AL. J Am Soc Mass Spectrom 2006, 17, 363–37512.25 min). Based on this observation and the appear-
ance of the fragment ions at m/z 170, 188, 218, 246, and
262 (average mass error associated with these fragment
ions is 2.7 ppm), we propose that one site of hydroxy-
lation is the ethyl group on the triazolone ring as is
noted with M8. Finally, the structures of the product
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metabolite M11. The proposed structure is pres
mechanism proposed by Kalgutkar and coworkers [1ions at m/z 225 (mass error  0.4 ppm) and 253 (mass
error  0.04 ppm) led us to propose 4-hydroxylation of
the 3-chlorophenyl ring as a second site of hydroxyla-
tion considering that 4-hydroxynefazodone is the only
metabolite detected from aromatic hydroxylation of
nefazodone [14 –17]. A similar conclusion was reached
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bolic pathways for nefazodone.
Of much interest in the present context was the facile
detection of the N-dephenylated piperazinemetabolites of
nefazodone namelyM11,M12, andM13, respectively, that
have been previously reported [16]. Consistent with the
loss of the 3-chlorophenyl moiety, there was a loss of the
diagnostic chlorine isotopic pattern in the full scan spectra.
In the present study, accurate mass full scan and MS/MS
spectra were used to predict and verify the structures.
Figure 10 shows the data-dependent MS/MS spectrum for
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further oxidation of M11.
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Figure 12. Full scan accurate mass product ion
of M11.the M11 metabolite. The predicted product ion structures
and corresponding mass errors are also provided. All of
the product ions of metabolite M11 as discerned from the
CID spectrum are identical to those observed in the mass
spectrum of parent nefazodone. Overall, the low mass
errors associated with each of these product ions and the
low mass error (1.1 ppm) observed in the full scan MS
analysis of M11 increased confidence in the assigned
metabolite structure.
Figures 11 and 12 show the product ion spectra for M12
and M13, respectively. M12 and M13 are derived from
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resulting product ion spectra with that shown in Figure 10
was used to determine the site of modification. For exam-
ple, Figure 11 shows the primary fragment ion at m/z 288
(14 mass units greater than the m/z 274 product ion
observed in Figure 10) is consistent with the formation of
the acylium ion (mass error 1.4 ppm) and suggestive of
lack of modification to the piperazine ring. The observed
product ions atm/z 140, 168, and 194 is consistent with the
site of oxidation residing on the propyl chain as opposed
to either the 5-ethyltriazolone motif or the phenoxyethyl
group. The observed acylium ion is consistent with P450-
catalyzed oxidation on the methylene group  to the
tertiary piperazine nitrogen in M11 affording amide M12.
Figure 12 shows the product ion spectrum for M13. The
primary fragment ions used to determine the site of
transformation were m/z 127, 152, 156, 262, and 290. The
presence of the m/z 127 product ion indicates the pipera-
zine ring was not the site of hydroxylation, rather the
detection of the m/z 156, 262, and 290 (average mass error
 2.1 ppm) show consistency with predicted structure
involving the site of monohydroxylation on the 5-ethyl-
triazolone moiety.
Combining the results from full scan MS and MS/MS
spectra provide a comprehensive list of nefazodone me-
tabolites listed in Table 2 obtained from one LC-MS/
MS/MS experiment. The chemical formulas listed were
predicted using Qual Browser and used for mass error
determination. The average mass error for all 16 identified
compounds was 1.8 ppm despite a 20-fold difference in
integrated peak areas. In addition, the RDB values calcu-
lated shows all values are related to the predicted struc-
tures increasing confidence in the predicted structures.
Conclusions
The present study outlines a facile method for identify-
Table 2. List of nefazodone and identified nefazodone metaboli
chemical formulas used were obtained from Qual Browser based
were compared to the predicted chemical formula
No. Chemical formula Rt (min) Integrated peak area E
1 C10H13O1N2Cl1 2.70 2.23e5
2 C19H30O3N5 7.19 5.75e6
3 C10H13N2Cl1 8.51 1.57e6
4 C19H30O2N5 8.90 1.60e7
5 C15H20O2N3 8.90 5.21e5
6 C19H28O3N5 9.17 5.28e6
7 C25H33O4N5Cl1 10.23 1.22e7
8 C15H21O3N3 10.65 4.11e6
9 C15H19O4N3 10.83 1.79e6
10 C15H19O4N3 11.01 6.25e5
11 C25H32O3N5Cl1 11.42 6.26e6
12 C23H28O3N5Cl1 12.16 2.19e6
13 C25H32O3N5Cl1 12.25 6.94e6
14 C25H32O2N5Cl1 13.35 5.01e7
15 C25H31O3N5Cl1 13.59 1.98e5
16 C25H32O3N5Cl1 13.68 6.25e5ing obvious and unanticipated metabolites in a singlechromatographic run using accurate mass analysis of
full scan MS and MS/MS spectra without the need for
an inclusion list. The success of the methodology is
based on fast scan speeds, high mass accuracy measure-
ments with large intra-scan dynamic range, and the use
of external calibration. Resulting mass spectral data can
then be processed manually by experts in the biotrans-
formation field or by predictive metabolite identifica-
tion software to generate possible parent and product
ion structures that are easily accepted or refuted using
accurate mass analysis, bond saturation, and chemical
formula ranges based on comparisons with mass spec-
tral data on the parent drug. Combination of these
features will undoubtedly improve confidence in the
assignments of chemical formulae and biotransforma-
tion sites on metabolites. Furthermore, the ability to
accurately measure product ion mass values without
the need for internal calibrants or multiple experimental
runs suggest that such analyses may be useful in early
stages of drug discovery to screen the metabolic pattern
of multiple compounds within a structural class or even
structurally diverse chemical series in a rapid and
iterative fashion and the knowledge of biotransforma-
tion pathways gained from such analysis could allow a
facile optimization of ADME attributes. In vitro metab-
olite identification studies are currently underway on
novel compounds with unknown biotransformation
pathways and at concentrations close to typical thera-
peutic range (0.1 to 0.5 M) to fully demonstrate the
merits of this instrumentation.
References
1. Watt, A. P.; Mortishire-Smith, R. J.; Gerhard, U.; Thomas, S. R. Metab-
olite Identification in Drug Discovery. Curr. Opin. Drug Discov. Dev.
2003, 6(1), 57–65.
2. Kalgutkar, A. S.; Soglia, J. R. Minimizing the Potential for Metabolic
om a 10 M incubation in human liver microsomes. Proposed
efazodone elemental composition and ranges. Mass accuracies
imental mass Theoretical mass RDB Mass error (ppm)
13.07921 213.07892 5.5 1.4
76.23505 376.23432 7.5 1.9
97.08452 197.08400 5.5 2.6
60.23981 360.23940 7.5 1.1
74.15567 274.15500 7.5 2.4
74.21829 374.21867 8.5 1.0
02.22086 502.22253 11.5 3.3
92.16608 292.16557 7.5 1.7
06.14557 306.14483 8.5 2.4
06.14539 306.14483 8.5 1.8
86.22742 486.22664 11.5 1.6
58.19559 458.19534 11.5 1.6
86.22748 486.22664 11.5 1.7
70.23224 470.23173 11.5 1.1
84.22167 484.21099 12.5 1.4
86.22754 486.22664 11.5 1.9tes fr
on n
xper
2
3
1
3
2
3
5
2
3
3
4
4
4
4
4Activation in Drug Discovery. Exp. Opin. Drug Metab. Toxicol. 2005, 1 1),
91–141.
375J Am Soc Mass Spectrom 2006, 17, 363–375 ORBITRAP MS IN METABOLITE IDENTIFICATION STUDIES3. Liu, D. Q.; Hop, C. E. C. A. Strategies for Characterization of Drug
Metabolites Using Liquid Chromatography-Tandem Mass Spectrome-
try in Conjunction with Chemical Derivatization and On-Line H/D
Exchange Approaches. J. Pharm. Biomed. Anal. 2005, 37(1), 1–18
4. Hop, C. E. C. A.; Yu, X.; Xu, X.; Singh, R.; Wong, B. K. Elucidation of
Fragmentation Mechanisms Involving Transfer of Three Hydrogen
Atoms Using a Quadrupole Time-of-Flight Mass Spectrometer. J. Mass
Spectrom. 2001, 36(5), 575–579
5. Yin, W.; Doss, G. A.; Stearns, R. A.; Chaudhary, A. G.; Hop, C. E.;
Frankin, R. B.; Kumar, S. A Novel P450-Catalyzed Transformation of the
2,2,6,6-Tetramethyl Piperidine Moiety to a 2,2-Dimethyl Pyrrolidine in
Human Liver Microsomes: Characterization by High Resolution Qua-
drupole-Time-of-Flight Mass Spectrometry and 1H-NMR. Drug Metab.
Dispos. 2003, 31(2), 215–223
6. Gangl, E.; Utkin, I.; Gerber, N.; Vouros, P. Structural Elucidation of
Metabolites of Ritonavir and Indinavir by Liquid Chromatography-
Mass Spectrometry. J. Chromatogr. A. 2002, 974(1/2), 91–101
7. Mutlib, A. E.; Shockcor, J. P. 2003; Application of LC/MS, LC/NMR,
NMR and Stable Isotopes in Identifying and Characterizing Metabo-
lites. Lee, J. S.; Obach, R. S.; Fisher, M. B., Eds.; In Drug Metabolizing
Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and
Development; p 33Marcel Dekker: New York, NY, Fontis Media:
Lausanne, Switzerland.
8. Li, L.; Chiarelli, M. P.; Branco, P. S.; Marques, M. M.; Goncalves, L. L.;
Beland, F. A. Differentiation of Isomeric C8-Substituted Alkylaniline
Adducts of Guanine by Electrospray Ionization and Tandem Quadru-
pole Ion Trap Mass Spectrometry. J. Am. Soc. Mass Spectrom. 2003,
14(12), 1488–1492
9. Hopfgartner, G.; Chernushevich, I. V.; Covey, T.; Plomley, J. B.; Bonner,
R. Exact Mass Measurement of Product Ions for the Structural Elucida-
tion of Drug Metabolites with a Tandem Quadrupole Orthogonal-
Acceleration Time-of-Flight Mass Spectrometer. J. Am. Soc. Mass Spec-
trom. 1999, 10(12), 1305–1314
10. Deroussent, A.; Re, M.; Hoellinger, H.; Vanquelef, E.; Duval, O.;
Sonnier, M.; Cresteil, T. In Vitro Metabolism of Ethoxidine by Human
CYP1A1 and Rat Microsomes: Identification of Metabolites by High-
Performance Liquid Chromatography Combined with Electrospray
Tandem Mass Spectrometry and Accurate Mass Measurements by
Time-of-Flight Mass Spectrometry. Rapid Commun. Mass Spectrom. 2004,
18(4), 474–482
11. Castro-Perez, J.; Plumb, R.; Granger, J. H.; Beattie, I.; Joncour, K.;
Wright, A. Increasing Throughput and Information Content for in Vitro
Drug Metabolism Experiments Using Ultra-Performance Liquid Chro-matography Coupled to a Quadrupole Time-of-Flight Mass
Spectrometer. Rapid Commun. Mass Spectrom. 2005, 19(6), 843–848
12. Hardman, M.; Makarov, A. A. Interfacing the Orbitrap Mass Analyzer
to an Electrospray Ion Source. Anal. Chem. 2003, 75(7), 1699–1705
13. Thevis, M.; Makarov, A. A.; Horning, S.; Schanzer, W. Mass Spectrom-
etry of Stanozolol and Its Analogs Using Electrospray Ionization and
Collision-Induced Dissociation with Quadrupole-Linear Ion Trap and
Linear Ion Trap-Orbitrap Hybrid Mass Snalyzers. Rapid Commun. Mass
Spectrom. 2005, 19(22), 3369–3378
14. Mayol, R. F.; Cole, C. A.; Luke, G. M.; Colson, K. L.; Kerns, E. H.
Characterization of the Metabolites of the Antidepressant Drug Nefaz-
odone in Human Urine and Plasma. Drug Metab. Dispos. 1994, 22(2),
304–311
15. Von Moltke, L. L.; Greenblatt, D. J.; Granda, B. W.; Grassi, J. M.;
Schmider, J.; Harmatz, J. S.; Shader, R. I. Nefazodone, Meta-Chlorophe-
nylpiperazine, and their Metabolites in Vitro: Cytochromes Mediating
Transformation, and P450-3A4 Inhibitory Actions. Psychopharmacology
1999, 145(1), 113–122.
16. Kalgutkar, A. S.; Vaz, A. D. N.; Lame, M. E.; Henne, K. R.; Soglia, J.;
Zhao, S. X.; Abramov, Y. A.; Lombardo, F.; Collin, C.; Hendsch, Z. S.;
Hop, C. E. C. A. Bioactivation of the Nontricyclic Antidepressant
Nefazodone to a Reactive Quinone-Imine Species in Human Liver
Microsomes and Recombinant Cytochrome P450 3A4. Drug Metab.
Dispos. 2005, 33(2), 243–253
17. Jemal, M.; Ouyang, Z.; Zhao, W.; Zhu, M.; Wu, W. W. A Strategy for
Metabolite Identification Using Triple-Quadrupole Mass Spectrometry
with Enhanced Resolution and Accurate Mass Capability. Rapid Com-
mun. Mass Spectrom. 2003, 17(24), 2732–2740
18. Hu, Q.; Noll, R. J.; Li, H.; Makarov, A.; Hardman, M.; Cooks, R. G. The
Orbitrap: A new Mass Spectrometer. J. Mass Spectrom. 2005, 40(4),
430–443
19. McLafferty, F. W.; Turecek, F. Interpretation of Mass Spectra, 4th ed.;
University Science Books: Mill Valley, CA, 1993, p 27.
20. Pittenauer, E.; Zehl, M.; Mistrik, R.; Allmaier, G. Evaluation of ESI-MSn
Ion Trap and MALDI-MSn Ion Trap/Reflectron TOF Mass Spectra
(n1–3) for Incorporation into a Searchable Database. Proceedings of the
52nd ASMS Conference on Mass Spectrometry and Allied Topics; Nashville,
TN 2004.
21. Mistrik, R. Comprehensive Database of Mechanisms of Peptide Frag-
mentation: A Key Step Towards Confident Identification of Proteins
Proceedings of the 52nd ASMS Conference on Mass Spectrometry and Allied
Topics; Nashville, TN 2004.
